Current Report Filing (8-k)
2022年7月23日 - 2:15AM
Edgar (US Regulatory)
0001632121
false
0001632121
2022-07-18
2022-07-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 18, 2022
|
BALANCE
LABS, INC. |
|
|
(Exact
name of registrant as specified in charter) |
|
Delaware |
|
333-202959 |
|
47-1146785 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
407
Lincoln Road, Suite 701, Miami Beach, Florida 33139
(Address
of Principal Executive Offices) (Zip Code)
(305)
907-7600
(Registrant’s
Telephone Number, Including Area Code)
Not
Applicable
(Former
Name or Former Address, If Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per shares |
|
BLNC |
|
OTC
Markets Group |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
July 18, 2022, Michael Farkas informed Balance Labs, Inc. (the “Company”) of his intention to resign as Chief Financial Officer
(“CFO”), effective as of July 18, 2022 (the “Separation Date”). Mr. Farkas resignation as CFO was not because
of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, including accounting
principles and practices. Mr. Farkas will continue to serve in his roles as the Company’s President, Chief Executive Officer, and
Chairman of the Board.
On
July 18, 2022, the Board of Directors of the Company (the “Board”) appointed Ari Feldman (age 49) to serve as the Company’s
CFO, effective July 18, 2022 (the “Commencement Date”). Over the past five years, Mr. Feldman has served as a CFO consultant.
In
connection with the appointment, Mr. Feldman will receive $21,000 annually, as compensation for his duties as CFO of the Company. Mr.
Feldman will serve as CFO until his earlier death, resignation, or removal.
There
is no arrangement or understanding between Mr. Feldman and any other persons, pursuant to which he was selected as CFO. Mr. Feldman has
not engaged in any transaction, or any currently proposed transaction, in which the Company was or is to be a participant and the amount
involved exceeds $120,000, and in which any related person had or will have a direct or indirect material interest. There is no employment
agreement between Mr. Feldman and the Company. There are no family relationships between Mr. Feldman and any director or executive officer
of the Company.
Item
9.01 Financial Statement and Exhibits.
(d)
Exhibits
Exhibit
Number |
|
Description
of Document |
|
|
|
104 |
|
Cover
page of this Current Report on Form 8-K formatted in Inline XBRL |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Balance
Labs, Inc. |
Date:
July 22, 2022 |
|
|
|
|
/s/
Michael D. Farkas |
|
Name: |
Michael
D. Farkas |
|
Title: |
Chief
Executive Officer |
Balance Labs (PK) (USOTC:BLNC)
過去 株価チャート
から 11 2024 まで 12 2024
Balance Labs (PK) (USOTC:BLNC)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Balance Labs Inc (PK) (その他OTC): 0 recent articles
その他のBalance Labs, Inc.ニュース記事